These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25501060)

  • 1. A qualitative study comparing the assay performance characteristics between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 scoring methods in mucinous epithelial ovarian cancer.
    Chen CK; Lee MY; Lin WL; Wang YT; Han CP; Yu CP; Chao WR
    Medicine (Baltimore); 2014 Dec; 93(27):e171. PubMed ID: 25501060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method.
    Chao WR; Lee MY; Ruan A; Sheng HP; Hsu JD; Han CP; Koo CL
    PLoS One; 2015; 10(11):e0142135. PubMed ID: 26566289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer.
    Chao WR; Lee MY; Lin WL; Chen CK; Lin JC; Koo CL; Sheu GT; Han CP
    Hum Pathol; 2014 Apr; 45(4):810-6. PubMed ID: 24656091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO/CAP guideline update.
    Chao WR; Lee MY; Lin WL; Koo CL; Sheu GT; Han CP
    Am J Surg Pathol; 2014 Sep; 38(9):1227-34. PubMed ID: 25133707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the 2017 ASCO/CAP guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO/CAP guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma.
    Chao WR; Lee MY; Lee YJ; Sheu GT; Han CP
    Virchows Arch; 2022 May; 480(5):1023-1030. PubMed ID: 35226147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
    Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
    Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
    Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
    Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors.
    Smithgall MC; Yemelyanova A; Mathew S; Gogineni S; He B; Zhang T; Robinson BD; Tu JJ
    Int J Gynecol Pathol; 2024 Mar; 43(2):134-139. PubMed ID: 37406458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
    Mentrikoski MJ; Stoler MH
    Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.
    Shah MV; Wiktor AE; Meyer RG; Tenner KS; Ballman KV; Green SJ; Sukov WR; Ketterling RP; Perez EA; Jenkins RB
    J Clin Oncol; 2016 Oct; 34(29):3502-3510. PubMed ID: 27458302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
    Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF; ;
    J Clin Oncol; 2007 Jan; 25(1):118-45. PubMed ID: 17159189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories.
    Nakhleh RE; Grimm EE; Idowu MO; Souers RJ; Fitzgibbons PL
    Arch Pathol Lab Med; 2010 May; 134(5):728-34. PubMed ID: 20441503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
    Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF;
    Arch Pathol Lab Med; 2007; 131(1):18-43. PubMed ID: 19548375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
    Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
    Varga Z; Noske A
    PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoplex LightCycler polymerase chain reaction quantitation of the HER2 gene for quality assurance of HER2/neu testing by immunohistochemistry and fluorescence in situ hybridization.
    Layfield LJ; Willmore-Payne C; Isom G; Holden JA
    Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):562-7. PubMed ID: 18948825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry.
    Muller KE; Marotti JD; Memoli VA; Wells WA; Tafe LJ
    Am J Clin Pathol; 2015 Aug; 144(2):247-52. PubMed ID: 26185309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.